Therapeutic Asset Ratings
1,028 results matching 1 filter
129,767 assets · 8,707 sponsors · 3,128 indications
Methodology v0.2
Filters
1
Highest Rated
Advanced Phase
Alphabetical
Recently Updated
Asset
Sponsor
Phase
Rating
Trastuzumab Deruxtecan
HRR Deficiency
Eisbach Bio GmbH
P1/2
CC
(47)
Trastuzumab Deruxtecan
Soft Tissue Sarcoma
GI Innovation, Inc.
P1/2
CC
(47)
Trastuzumab Deruxtecan
Lung Cancer
National Cancer Institute (NCI)
P1/2
CC
(47)
Trastuzumab Deruxtecan
Malignant Pancreatic Neoplasm
National Cancer Institute (NCI)
P1/2
CC
(47)
Trastuzumab Emtansine
Gastric Adenocarcinoma
Boehringer Ingelheim
P1/2
CC
(47)
Antibody drug conjugate composed of a humanized monoclonal antibody targeting CLDN18.2 and linker-payload MC-VC-PAB-MMAE
Pancreatic Neoplasm
Shanghai Zhongshan Hospital
P2
CC
(46)
ARX 788
Breast Cancer
QuantumLeap Healthcare Collaborative
P2
CC
(46)
CAB-ROR2-ADC (BA-3021)
Ovarian Cancer
Canadian Cancer Trials Group
P2
CC
(46)
hlx43
Ovarian Cancer
Shanghai Henlius Biotech
P2
CC
(46)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
Colorectal Cancer
Sichuan Baili Pharmaceutical Co., Ltd.
P2
CC
(46)
IMMUNOGLOBULIN G1 (DE-450-LYSINE), ANTI-(HUMAN TYROSINE KINASE RECEPTOR AXL) (HUMAN-MUS MUSCULUS MONOCLONAL BA301 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS MONOCLONAL BA301 .KAPPA.-CHAIN, DIMER, THIOETHER WITH N-(((4-((N-(6-(3-MERCAPTO-2,5-DIOXO-1-PYRROLIDINYL)-1-OXOHEXYL)-L-VALY L-N5-(AMINOCARBONYL)-L-ORNITHYL)AMINO)PHENYL)METHOXY)CARBONYL)-N-METHYL-L-VALYL-N-((1S,2R)-4-((2S)-2-((1R,2R)-3-(((1R,2S)-2-HYDROXY-1-METHYL-2-PHENYLETHYL)AMINO)-1-METHOXY-2-METHYL-3-OXOPROPYL)-1-PYRROLIDINYL)-2-METHOXY-1-((1S)-1-METHYLPROPYL)-4-OXOBUTYL)-N-METHYL-L-VALINAMIDE
Ovarian Cancer
Canadian Cancer Trials Group
P2
CC
(46)
immunoglobulin G1-kappa, anti-[Homo sapiens CDH6(cadherin 6, K-cadherin (foetal kidney), cadherin 6 type 2)], humanized monoclonal antibody conjugated to deruxtecan, comprising a linker and a camptothecin derivative
Cancer
Daiichi Sankyo
P2
CC
(46)
Loncastuximab Tesirine
Follicular Lymphoma
Universität Münster
P2
CC
(46)
rc48
Ovarian Cancer
Jiangsu Cancer Institute & Hospital
P2
CC
(46)
Sacituzumab Tirumotecan
Prostate Cancer
Virginia Commonwealth University
P2
CC
(46)
Trastuzumab Deruxtecan
Multiple Myeloma
American Society of Clinical Oncology
P2
CC
(46)
Trastuzumab Deruxtecan
Prostate Cancer
AstraZeneca
P2
CC
(46)
ABT-700-VCMMAE
Advanced Solid Tumors Cancer
AbbVie
P1
CC
(46)
Inotuzumab Ozogamicin
Adult Acute Lymphoblastic Leukemia
Ruijin Hospital
P1
CC
(46)
Tisotumab Vedotin
Cancer
Zai Lab (Shanghai) Co., Ltd.
P1
CC
(46)
Trastuzumab Deruxtecan
Refractory Malignant Neoplasm
M.D. Anderson Cancer Center
P1
CC
(46)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide
Lung Cancer
Bristol-Myers Squibb
P1/2
CC
(46)
Precemtabart Tocentecan
Neoplasm
EMD Serono Research & Development Institute, Inc.
P1/2
CC
(46)
rc48-adc
Endometrial Cancer
Hutchmed
P1/2
CC
(46)
rc48-adc
Renal Cell Carcinoma
HiFiBiO Therapeutics
P1/2
CC
(46)
Showing 701 to 725 of 1,028 assets
Previous
Page 29 of 42
Next
